Autopsy report · NCT05764239

Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)

“Based on a review of interim data from participants in the dose-escalation phase, it was determined that the study was unlikely to meet the primary endpoint.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 8 months before it stopped.
• 35 participants enrolled.
• Results were posted on the registry 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Synlogic

Sponsor type

Industry

Conditions

Phenylketonuria

Interventions

SYNB1934v1; Placebo

Participants

35

Sites

21

Countries

Canada, Georgia, Turkey (Türkiye), United States

Trials that died the same way

• 68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma
  “dose escalation trial, and the first 3 patients (who made up a cohort) were all accrued” (74% match in meaning)
• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
  “Results of a planned interim analysis did not show significant effects for any of the 3 AIN dose regimens versus placebo on any primary or secondary endpoint” (72% match in meaning)
• Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
  “Study was terminated at completion of the Phase 1 dose escalation due to loss of financial support.” (68% match in meaning)
• Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease
  “Per protocol, 3 sequential dose cohorts were planned. Study discontinued by Sponsor based upon serious adverse events in first 2 of 3 participants in Cohort 1.” (66% match in meaning)
• LBH589 in Refractory Myelodysplastic Syndromes (MDS)
  “Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.